Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is testing a new treatment called mezigdomide in patients with multiple myeloma that has come back after getting better. Mezigdomide works by binding to a protein and causing the cancer cells to die. The study will see if giving mezigdomide after another treatment called Abecma CAR T cell therapy can make the CAR T cells last longer in the body.
This study is testing a new treatment called mezigdomide in patients with multiple myeloma that has come back after getting better. Mezigdomide works by binding to a protein and causing the cancer cells to die. The study will see if giving mezigdomide after another treatment called Abecma CAR T cell therapy can make the CAR T cells last longer in the body.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor [CAR] T-cell therapy) in patients with multiple myeloma that has come back after a period of improvement (relapsed). CC-92480 works by binding to a protein called CRBN that triggers the breakdown of proteins: Ikaros and Aiolos, leading to cell death in multiple myeloma cells. Giving mezigdomide after Abecma CAR T cell therapy may extending the amount of time that the CAR T cells persist in the body in patients with relapsed multiple myeloma.
This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor [CAR] T-cell therapy) in patients with multiple myeloma that has come back after a period of improvement (relapsed). CC-92480 works by binding to a protein called CRBN that triggers the breakdown of proteins: Ikaros and Aiolos, leading to cell death in multiple myeloma cells. Giving mezigdomide after Abecma CAR T cell therapy may extending the amount of time that the CAR T cells persist in the body in patients with relapsed multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: